FM
LFCR icon

Fondren Management’s Lifecore Biomedical LFCR Stock Holding History

Fondren Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-20,000
Closed -$187K – 83
2019
Q2 		$187K Buy
+20,000
New +$202K 0.18% 65

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WC
Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

Fondren Management's LFCR Position: Q3 2019 in Review

Fondren Management sold out of Lifecore Biomedical (LFCR) in Q3 2019, closing a stake of 20,000 shares — an estimated $187K sold.

Fondren Management first reported a position in LFCR in Q2 2019 and held it in 1 quarter. The position peaked at $187K in Q2 2019. 104 funds tracked by Wall St. Rank hold LFCR as of Q3 2019.

  • Fondren Management reported no remaining Lifecore Biomedical position as of Q3 2019 after selling out during the quarter.
  • Fondren Management sold 20,000 Lifecore Biomedical shares in Q3 2019, an estimated $187K.
  • Fondren Management first reported a position in Lifecore Biomedical in Q2 2019 and held it in 1 quarter.
  • Fondren Management's Lifecore Biomedical position peaked at $187K in Q2 2019.
  • 104 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2019.

Based on Fondren Management's 13F filing for Q3 2019, filed 14 Nov 2019.